63 related articles for article (PubMed ID: 9757278)
1. [Iodinated contrast media].
Revel D
J Radiol; 1998 Jun; 79(6):512. PubMed ID: 9757278
[No Abstract] [Full Text] [Related]
2. Nonfatal adverse reactions to iodinated contrast media: spontaneous reporting to the U.S. Food and Drug Administration, 1978-1994.
Spring DB; Bettmann MA; Barkan HE
Radiology; 1997 Aug; 204(2):325-32. PubMed ID: 9240515
[TBL] [Abstract][Full Text] [Related]
3. Delayed adverse reaction to sodium ioxaglic acid-meglumine.
Kanny G; Marie B; Hoen B; Trechot P; Moneret-Vautrin DA
Eur J Dermatol; 2001; 11(2):134-7. PubMed ID: 11275812
[TBL] [Abstract][Full Text] [Related]
4. Deaths related to iodinated contrast media reported spontaneously to the U.S. Food and Drug Administration, 1978-1994: effect of the availability of low-osmolality contrast media.
Spring DB; Bettmann MA; Barkan HE
Radiology; 1997 Aug; 204(2):333-7. PubMed ID: 9240516
[TBL] [Abstract][Full Text] [Related]
5. [Severe reactions to iodinated contrast agents: is anaphylaxis responsible?].
Dewachter P; Mouton-Faivre C
J Radiol; 2001 Sep; 82(9 Pt 1):973-7. PubMed ID: 11591924
[TBL] [Abstract][Full Text] [Related]
6. Acute and subacute stent occlusion; risk-reduction by ionic contrast media.
Scheller B; Hennen B; Pohl A; Schieffer H; Markwirth T
Eur Heart J; 2001 Mar; 22(5):385-91. PubMed ID: 11207080
[TBL] [Abstract][Full Text] [Related]
7. [Effect of various roentgen contrast media on pancreatic and liver enzymes in ERCP].
Rambow A; Staritz M; Manns M; Hütteroth T; Meyer zum Büschenfelde KH
Schweiz Rundsch Med Prax; 1988 Jan; 77(4):55-7. PubMed ID: 3347790
[No Abstract] [Full Text] [Related]
8. Skin reaction to contrast medium.
Gonzalo-Garijo MA; de Argila D; Pimentel JJ; Alejo M; García-Menaya JM
Allergy; 1997 Aug; 52(8):875-6. PubMed ID: 9284992
[No Abstract] [Full Text] [Related]
9. A rare case of acute contrast-induced sialadenitis after percutaneous coronary intervention.
Shacham Y; Havakuk O; Roth A
Isr Med Assoc J; 2013 Oct; 15(10):652-3. PubMed ID: 24266096
[No Abstract] [Full Text] [Related]
10. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables.
Dangas G; Iakovou I; Nikolsky E; Aymong ED; Mintz GS; Kipshidze NN; Lansky AJ; Moussa I; Stone GW; Moses JW; Leon MB; Mehran R
Am J Cardiol; 2005 Jan; 95(1):13-9. PubMed ID: 15619387
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of renal function.
Becker JA
Radiology; 1991 May; 179(2):337-8. PubMed ID: 2014272
[No Abstract] [Full Text] [Related]
12. Adverse drug reaction reporting.
Somberg JC
Am J Ther; 2000 Aug; 7(4):227-8. PubMed ID: 11486155
[No Abstract] [Full Text] [Related]
13. Ultrastructural evaluation of the effects of the contrast media on the rat kidney.
Cağlar Y; Mete UO; Kaya M
J Submicrosc Cytol Pathol; 2001 Oct; 33(4):443-51. PubMed ID: 11989778
[TBL] [Abstract][Full Text] [Related]
14. [Approaches to classifying adverse reactions of radiopaque substances].
Napolov IuK; Korobkova IZ; Chekavskaia OV; Gorgadze TT; Kalinichev SA
Vestn Rentgenol Radiol; 2006; (4):53-62. PubMed ID: 17633888
[No Abstract] [Full Text] [Related]
15. [Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography].
El Mahmoud R; Le Feuvre C; Le Quan Sang KH; Helft G; Beygui F; Batisse JP; Metzger JP
Arch Mal Coeur Vaiss; 2003 Dec; 96(12):1157-61. PubMed ID: 15248440
[TBL] [Abstract][Full Text] [Related]
16. Safety of ionic and nonionic contrast media.
Wolf GL
Radiology; 1998 Feb; 206(2):560-1. PubMed ID: 9457213
[No Abstract] [Full Text] [Related]
17. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
18. US Food and Drug Administration: adverse event reporting.
Graham AA
CRNA; 1998 Nov; 9(4):135-8. PubMed ID: 9866488
[TBL] [Abstract][Full Text] [Related]
19. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
[TBL] [Abstract][Full Text] [Related]
20. Toward improved adverse event/suspected adverse drug reaction reporting.
Gross R; Strom BL
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
[No Abstract] [Full Text] [Related]
[Next] [New Search]
